Overview
HAE market data
Price History
HAE price chart
Valuation & Profitability
- P/E (TTM)
- 43.22 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.05 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.60 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 7.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $47.32 – $92.25 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.2B · P/B 3.21 · P/S 3.08.
Company News
Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $92Benzinga · Aug 7, 2026, 8:53 PM
JP Morgan Maintains Neutral on Haemonetics, Raises Price Target to $86Benzinga · Aug 7, 2026, 3:59 PM
BTIG Maintains Buy on Haemonetics, Raises Price Target to $96Benzinga · Aug 6, 2026, 6:25 PM
Haemonetics Q1 Adj. EPS $1.14 Beats $1.08 Estimate, Sales $339.380M Beat $327.894M EstimateBenzinga · Aug 6, 2026, 10:03 AM
Haemonetics Widens FY2027 Sales Guidance from $1.410B-$1.427B to $1.401B-$1.441B vs $1.402B EstBenzinga · Aug 6, 2026, 10:02 AM
Haemonetics Announces 1,623-Patient Study Of VASCADE MVP XL Closure System Showing 92.5% Same-Day Discharge Rate And 1.2% Overall Vascular ComplicationsBenzinga · Aug 3, 2026, 8:25 PM
8-K filing — HAEMONETICS CORP (HAE)SEC EDGAR · Jul 28, 2026, 8:28 PM
Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated TechnologiesGlobenewswire Inc · Jul 24, 2026, 3:15 PM
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $90Benzinga · Jul 15, 2026, 6:28 PM
BTIG Reiterates Buy on Haemonetics, Maintains $84 Price TargetBenzinga · Jun 26, 2026, 11:40 AM